… of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment
of patients affected by advanced non-small-cell lung cancer with the absence of epidermal …

… Overall gefitinib resulted more hepatotoxic while erlotinib resulted more toxic in terms of …
prospective phase III studies comparing gefitinib and erlotinib. However, a randomized phase II …

… -small-cell lung cancer (NSCLC) had been focused on monotherapy of gefitinib, erlotinib, or
… inhibitors are one of candidates for next strategy for EGFR-mutated tumor. We conducted a …

… is associated with a worse prognosis in lung cancer. Likewise, MET expression and/or … lung
cancer,7, 8 and both were observed in a slightly higher proportion of patients in the erlotinib …

… advanced non–small cell lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment
… TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin …

… The National Cancer Institute has recently approved a large phase III cooperative group trial
… in stage III NSCLC, in which erlotinib or crizotinib is given as a single agent for 3 months in …

… shown to have reduced exposure to erlotinib, which may contribute to poorer clinical outcomes
[4]. The phase III CurrentS study investigated a 300 mg erlotinib dose compared with the …

… The BR.21 study was a phase 3 trial of erlotinib involving patients who had had progression
… lung cancer. Patients were randomly assigned in a 2:1 ratio to receive 150 mg of erlotinib …

… On the basis of these findings, we have planned a phase III study to comprehensively evaluate
the efficacy, and safety of combination therapy with erlotinib plus ramucirumab compared …

… the erlotinib arm of the randomized phase III BR.21 study). Assuming a two-sided α = .05%
and 80% power, the sample size was calculated to be 154 patients. The primary analysis was …